美辉瑞药厂与德BioNTech研发新冠疫苗临床测试成功产生抗体 效用待证
德国生物科技公司BioNTech与美国辉瑞药厂合作研发的新冠疫苗,以早期人体临床测试效果良好,为目前为止第四款出现同类表现的新冠疫苗。Moderna、CanSino Biologics及Inovio Pharmaceuticals早前亦作相类声称,即注射疫苗後成功产生抗体。
BioNTech表示,向24名自愿者注射两剂测试疫苗,产生抗体较感染新冠人士为多,当中四分三自愿者在第二次注射後出现轻微发热,为高剂量测试群组进行的第三次注射则未有进行。公司称,其後将进行更大规模测试,以检视有关抗体能否对新冠病毒产生免疫力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.